title: A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy.
abstract: BACKGROUND
  The ActiPatch(®) (BioElectronics Corporation, MD, USA) pulsed shortwave therapy device has been shown to be clinically effective in three double-blind randomized controlled pain studies. However, the effectiveness of this device in a broader population of chronic musculoskeletal pain sufferers, affected by a variety of etiologies in different regions of the body, has not been studied.
  
  
  OBJECTIVE
  The objective of this registry study was to assess the effectiveness and satisfaction of the ActiPatch device in the general population of chronic pain sufferers.
  
  
  METHODS
  A total of 44,000 subjects completed the trial, with 5000 assessments of the device collected.
  
  
  CONCLUSIONS
  The ActiPatch device appears to provide a clinically meaningful reduction of chronic musculoskeletal pain affecting different locations of the body caused by a variety of etiologies.
authors.affiliation: BioElectronics Corporation, 4539 Metropolitan Ct, Frederick, Maryland, MD 21704, USA.
authors.forename: Ian M
authors.initials: IM
authors.lastname: Rawe
authors.affiliation: BioElectronics Corporation, 4539 Metropolitan Ct, Frederick, Maryland, MD 21704, USA.
authors.forename: Deepak C
authors.initials: DC
authors.lastname: Kotak
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D059350:Chronic Pain / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D059352:Musculoskeletal Pain / Q000628:therapy*; D010147:Pain Measurement; D011788:Quality of Life; D012042:Registries; D012780:Short-Wave Therapy; D016896:Treatment Outcome; D006113:United Kingdom; D055815:Young Adult
keywords: chronic pain; noninvasive; over-the-counter; pulsed shortwave therapy; therapy